| 前收市價 | 54.31 |
| 開市 | 46.50 |
| 買盤 | 46.30 |
| 賣出價 | 47.95 |
| 拍板 | 130.00 |
| 到期日 | 2026-01-16 |
| 今日波幅 | 46.50 - 46.50 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 189 |
Yahoo財經美股日誌｜道指全月今年最佳 納指漲近7%
美股在5月最後交易日個別發展，道瓊斯指數發力，升1.5%，以點數計大升逾570點，為今年以來最佳單日表現。納指周五平收，不過五月大升6.88%，跑贏另外兩指數。個人消費支出（PCE）4月份增長放緩，符合市場預期，美國國債息率稍為回落，市場維持九月份50%機會減息的預期。個別業績股大幅波動，電腦廠商Dell業績雖然好過預期，大跌18%，服裝零售商業績好過預期，大升28%。
BenzingaModerna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
On Friday, the FDA approved Moderna Inc’s (NASDAQ:MRNA) mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine to protect adults aged 60 and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna, the first being the famed COVID-19 vaccine. Earlier this month, the FDA, citing administrative constraints, delayed the review of the vaccine’s applicat
Investor's Business DailyModerna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.
